Croda International PLC (CRDA)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 3,636.00 |
|---|---|
| 52-week range | 2,488.00 – 3,659.00 |
| Return, 1 month / 3 months | +11.8% / +29.0% |
| Return, 1 year / 3 years | +27.2% / −2.3% |
| Trend | Uptrend |
| RSI (14) | 74 |
| Volatility (1 year) | 29.0% |
| Worst drawdown (1 year) | -21.6% |
| Average daily value traded | 1,591.39M GBX |
| Dividend yield | 3.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Croda International is a specialty chemicals company based in the United Kingdom. It develops and makes ingredients used in personal care and cosmetic products, such as skin care and hair care formulations, and supplies ingredients for healthcare and pharmaceutical applications. It also provides specialty chemicals for crop protection, coatings, lubricants and other industrial uses. Its customers are manufacturers in the consumer care, life sciences and industrial markets, who use these ingredients in their own products.
Croda International PLC trades under the code CRDA on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Croda International PLC (CRDA) trades on the London Exchange in UK. It last closed at GBX 3,636.00 on 23 October 2026.
Its price-based Market X-Ray is 79 out of 100 (a strong price profile), ranking 95 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 27.2% and over the last three months it rose 29.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.8% | ||
| From 52-week high | 0.0% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 29.0% | ||
| 6-month return | 24.0% | ||
| 12-month return, skipping the last month | 13.8% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.6% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 1,591.39M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 47 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.4% |
|---|---|
| 1 month | +11.8% |
| 3 months | +29.0% |
| 6 months | +24.0% |
| 1 year | +27.2% |
| 3 years | −2.3% |
| 5 years | −55.0% |
Signals
| 50-day / 200-day average | 3,339.46 / 2,985.74 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 73.77 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Aug 2026 | GBP 0.4800 |
| 9 Apr 2026 | GBP 0.6300 |
| 28 Aug 2025 | GBP 0.4800 |
| 10 Apr 2025 | GBP 0.6300 |
| 5 Sep 2024 | GBP 0.4700 |
| 18 Apr 2024 | GBP 0.6200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.